FRX News 97.46 06/19/2014 04:57:43 Forest Laboratories (FRX)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Forest Laboratories (FRX) 97.46 $FRX

Nasdaq, S&P 500 Rally To New Highs After Fed Meeting
at Investor's Business Daily - Wed Jun 18, 3:20PM CDT
The major averages rallied after the Fed said it would keep interest rates near zero and trimmed monthly bond purchases by $10 billion, to $35 billion. The Fed lowered its 2014 economic growth forecast to between 2.1% and 2.3%, from 2.9%, but said...

Next Resistance Level for Forest Laboratories (FRX) is $99.30
Comtex SmarTrend(R) - Wed Jun 18, 9:02AM CDT
Shares of Forest Laboratories (NYSE:FRX) have bullishly opened above the pivot of $96.19 today and have reached the first resistance level of $97.94. Analysts will be watching for a cross of the next upside pivot targets of $99.30 and $102.41.

Forest Obtains Six Months U.S. Pediatric Exclusivity for NAMENDA(R) and NAMENDA XR(R)
Business Wire - Wed Jun 18, 7:30AM CDT
Forest Laboratories, Inc. (NYSE:FRX) announced today that the U.S Food and Drug Administration (FDA) has granted pediatric exclusivity for memantine hydrochloride. Based on this decision, an additional six months of U.S. market exclusivity will attach to the patents that are listed in FDA's Orange Book for NAMENDA and NAMENDA XR.

Allergan, Actavis Top Big Cap Pharmas Amid M&A Flurry
at Investor's Business Daily - Wed Jun 18, 7:02AM CDT
With 2014 already the strongest year for mergers and acquisitions since 2007, the flurry of dealmaking has given shares of some large drugmakers a shot in the arm -- or face, in the case of Botox maker Allergan (AGN). But not all offers have been...

PharmaPoint: Major Depressive Disorder Report 2014 - Current and Future Players
M2 - Wed Jun 18, 4:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wdh27g/pharmapoint) has announced the addition of the "PharmaPoint: Major Depressive Disorder - Current and Future Players" report to their offering. The report identifies and analyses the key companies shaping and driving the global Major Depressive Disorder market. The report provides insight into the competitive Major Depressive Disorder landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by Our team of industry experts. Scope - Investigation of current and future market competition for Major Depressive Disorder. - Competitor assessment - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. - Strategic assessment of Major Depressive Disorder sector through market impact analysis, future market scenario and company analysis Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Market Outlook - Forecast - Drivers and Barriers - Global Issues 4 Current and Future Players - Trends in Corporate Strategy - Company Profiles 5 Appendix Companies Mentioned - Lundbeck - Forest Laboratories (Actavis) - Eli Lilly - Pfizer - Otsuka Pharmaceutical - AstraZeneca - Takeda Pharmaceutical - Alkermes - Euthymics Bioscience - Naurex - e-Therapeutics For more information visit http://www.researchandmarkets.com/research/wd...harmapoint

Viibryd (Major Depressive Disorder) - Forecast and Market Analysis to 2023
M2 - Wed Jun 18, 3:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5mvpkt/viibryd_major) has announced the addition of the "Viibryd (Major Depressive Disorder) - Forecast and Market Analysis to 2023" report to their offering. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023. Viibryd (vilazodone) is an SSRI and a 5HT1A receptor partial agonist indicated for the treatment of patients with MDD. Viibryd was licensed from Merck KGaA and developed by Forest (Actavis). Currently, it is only available in the US market and, in 2013, generated sales of $162.5m (Forest Laboratories, 2014). Scope - Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Viibryd including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Viibryd for the US from 2013 to 2023. - Sales information covered for the US. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Viibryd (Vilazodone) 7 Appendix For more information visit http://www.researchandmarkets.com/research/5m...bryd_major

Actavis' shareholders approves planned acquisition of Forest for about USD25bn in cash and stock
M2 - Wed Jun 18, 3:52AM CDT
Specialist pharmaceutical company Actavis (NYSE:ACT) stated on Tuesday that all proposals related to its planned acquisition of Forest Laboratories (NYSE:FRX) were approved by their respective shareholders at the recent shareholder meetings.

Actavis and Forest Shareholders Approve Proposals Related to Actavis' Planned Acquisition of Forest
Business Wire - Tue Jun 17, 3:17PM CDT
Actavis plc (NYSE:ACT) and Forest Laboratories, Inc. (NYSE:FRX) today announced that, at shareholder meetings held today, all proposals related to Actavis' planned acquisition of Forest were approved by both Actavis' and Forest's shareholders.

Valeant Receives FDA's Clearance for Restylane - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 17, 2:05PM CDT
Valeant Pharmaceuticals International, Inc. (VRX) announced that the FDA issued a marketing clearance for its Restylane Silk Injectable Gel with 0.3% Lidocaine.

Global Autism Clinical Trials Review 2014
M2 - Tue Jun 17, 9:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vhfbw6/autism_global) has announced the addition of the "Autism Global Clinical Trials Review, H1, 2014" report to their offering. Autism Global Clinical Trials Review, H1, 2014 provides data on the Autism clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Autism. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Autism. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - Autism Speaks, Inc. - Seaside Therapeutics, LLC - Forest Laboratories, Inc. - Johnson & Johnson - Otsuka Holdings Co., Ltd. - F. Hoffmann-La Roche Ltd. - Bristol-Myers Squibb Company - Coronado Biosciences, Inc. - ZonMw - Dainippon Sumitomo Pharma Co., Ltd. - National Institute of Mental Health - Massachusetts General Hospital - Tehran University of Medical Sciences - Eunice Kennedy Shriver National Institute of Child Health and Human Development - Hugo W. Moser Research Institute at Kennedy Krieger, Inc. - Stanford University - The University of Hong Kong - University of California, Los Angeles - Mount Sinai Hospital - University of California, San Francisco For more information visit http://www.researchandmarkets.com/research/vh...ism_global

COPD Foundation Releases Groundbreaking COPE Survey Results: Low Patient Awareness About COPD Exacerbations Poses Barrier to Effective Management
Business Wire - Tue Jun 17, 8:37AM CDT
Patients with chronic obstructive pulmonary disease (COPD) may need more education and better dialogue with their physicians to effectively manage the progressive respiratory condition and potentially life-threatening complications known as exacerbations (or flare-ups), according to key findings from the new, two-part national COPE (Chronic Obstructive Pulmonary Experience) Survey initiative released today by the COPD Foundation.

Fetzima (Major Depressive Disorder) - Forecast and Market Analysis to 2023
M2 - Tue Jun 17, 6:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lnvwv5/fetzima_major) has announced the addition of the "Fetzima (Major Depressive Disorder) - Forecast and Market Analysis to 2023" report to their offering. Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023. Fetzima (levomilnacipran) is an SNRI indicated for the treatment of MDD and is only available in the US. It gained FDA approval in July 2013 and was launched in December 2013. The product was developed by Forest (Actavis) following a partnership with Pierre Fabre. According to this agreement, Forest Laboratories is responsible for the clinical development and commercialization of Fetzima in the US and Canada, while Pierre Fabre is responsible for manufacturing and supplying the active pharmaceutical ingredient. Scope - Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Fetzima including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Fetzima for the US from 2013 to 2023. - Sales information covered for the US. Key Topics Covered: 1 Table of Contents 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Fetzima (Levomilnacipran) 7 Appendix For more information visit http://www.researchandmarkets.com/research/ln...zima_major

Idiopathic (Essential) Hypertension - Pipeline Review, H1 2014
M2 - Mon Jun 16, 5:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h6fdl5/idiopathic) has announced the addition of the "Idiopathic (Essential) Hypertension - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic (Essential) Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic (Essential) Hypertension and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Idiopathic (Essential) Hypertension - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Idiopathic (Essential) Hypertension pipeline depth and focus of Indication therapeutics Companies Mentioned: - Novartis AG - Actelion Ltd - Forest Laboratories, Inc. - Les Laboratoires Servier SAS - Bayer AG - XOMA Corporation - Ahn-Gook Pharmaceutical Co., Ltd. - PhaseBio Pharmaceuticals, Inc. - Lee's Pharmaceutical Holdings Limited - NanoForm Therapeutics Ltd. For more information visit http://www.researchandmarkets.com/research/h6fdl5/idiopathic

Will Forest Labs Retain Namenda Market Share? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 13, 11:00AM CDT
Forest Laboratories, Inc. (FRX) has postponed the final phase of switching to late 2014 and intends to continue marketing Namenda IR till the fall of 2014.

Actavis Announces Receipt of Requisite Consents and Expiration of Consent Solicitations for Forest Laboratories Senior Notes
PR Newswire - Thu Jun 12, 5:16PM CDT
Actavis plc (NYSE: ACT) today announced that Forest Laboratories, Inc. (NYSE: FRX) has received valid consents (the "Requisite Consents" from holders of a majority in aggregate principal amount of each series of Forest's securities listed in the table below (the "FRX Notes" to the elimination of Forest's contractual registration rights obligations with respect to each series of FRX Notes (the "Proposed Amendments" (collectively, the "Consent Solicitations" . As consideration for the Requisite Consents, Actavis will fully, unconditionally and irrevocably guarantee (each, a "ACT Guarantee" and, together, the "ACT Guarantees" each series of FRX Notes, subject to the closing of Actavis' pending acquisition (the "Acquisition" of Forest and certain other customary conditions. The terms and conditions of the Consent Solicitations are described in the Offering Memorandum/Consent Solicitation Statement, dated May 22, 2014 (as may be amended or supplemented from time to time, the "Consent Solicitations Statement" .

Forest Laboratories, Inc. Announces Receipt of Requisite Consents and Expiration of Consent Solicitations for Certain of its Senior Notes
Business Wire - Thu Jun 12, 4:00PM CDT
Forest Laboratories, Inc. (NYSE:FRX) today announced that it had received valid consents (the "Requisite Consents" from holders of a majority in aggregate principal amount of each series of its securities listed in the table below (the "FRX Notes" to the elimination of Forest's contractual registration rights obligations with respect to each series of FRX Notes (the "Proposed Amendments" (collectively, the "Consent Solicitations" . As consideration for the Requisite Consents, Actavis plc (NYSE:ACT) will fully, unconditionally and irrevocably guarantee (each, a "ACT Guarantee" and, together, the "ACT Guarantees" each series of FRX Notes, subject to the closing of Actavis' pending acquisition (the "Acquisition" of Forest and certain other customary conditions. The terms and conditions of the Consent Solicitations are described in the Offering Memorandum/Consent Solicitation Statement, dated May 22, 2014 (as may be amended or supplemented from time to time, the "Consent Solicitations Statement" .

2014 Report on the International Antibacterial Drugs (minoglycosides, B-Lactams, Tetracyclines, Sulfonamides, Quinolones/ Fluoroquinolones, Macrolides and Phenicols) Market - Forecast to 2019
PR Newswire Europe - Thu Jun 12, 7:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l2jzql/antibacterial [http://www.researchandmarkets.com/research/l2jzql/antibacterial]) has announced the addition of the "Antibacterial Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" [http://www.researchandmarkets.com/research/l2jzql/antibacterial] report to their offering.

Consent Expiry Extensions, Collaborations, Grants, Conference Presentations, and FDA Approvals - Analyst Notes on Forest Laboratories, Intuitive Surgical, Horizon Pharma, Cubist and BDSI
PR Newswire - Thu Jun 12, 5:10AM CDT
Today, Analysts Review released its analysts' notes regarding Forest Laboratories, Inc. (NYSE: FRX), Intuitive Surgical, Inc. (NASDAQ: ISRG), Horizon Pharma Inc (NASDAQ: HZNP), Cubist Pharmaceuticals Inc (NASDAQ: CBST) and BioDelivery Sciences International, Inc. (NASDAQ: BDSI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3640-100free.

Arrhythmias - Pipeline Review, H1 2014
M2 - Thu Jun 12, 3:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3k97mr/arrhythmias) has announced the addition of the "Arrhythmias - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Arrhythmias, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arrhythmias and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Arrhythmias - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Arrhythmias and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Arrhythmias products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Mentioned: - Gilead Sciences - Forest Laboratories - Orion - Compugen - SciFluor For more information visit http://www.researchandmarkets.com/research/3k...rrhythmias
Scroll down for more posts ▼

Top 10 Most Recent News Articles

S&P Global's December 8 Talk Puts Guidance in Focus

Updated Category News Views 54

A 35-minute fireside chat can be a whole lot of nothing, or it can leave a useful breadcrumb trail for shareholders willing to listen closely. S&P Global has put December 8, 2026 on the calendar, when Chief Executive Officer Martina Cheung is scheduled to appear at Goldman Sachs' 2026 Financial Services Conference in New York. Her slot runs from 5:00 p.m. to 5:35 p.m....

Continue Reading
California Rideshare Data Exposes an Insurance Gap

Updated Category News Views 52

Three California counties carried an outsized share of rideshare traffic, and the insurance fine print is where this story gets uncomfortable. A review by Mendez & Sanchez says Los Angeles, San Francisco, and San Diego counties accounted for nearly two-thirds of statewide rideshare trips between September 2019 and August 2020. That is an old snapshot, sure, but it points...

Continue Reading
Nevada’s Space Academy Bid Has Assets, Not a Win Yet

Updated Category News Views 29

Desert acreage and a moon-landing backstory make for a handsome pitch, but Nevada is still standing at the starting line. The state has submitted its official response to NASA’s Request for Information for a proposed United States Space Academy, and the new promotional video is meant to show why the Silver State belongs in the conversation. Fair enough. There is real...

Continue Reading
Mars Sets $2 Billion Debt Tender With Kellanova Notes

Updated Category News Views 124

A two-billion-dollar vacuum cleaner just switched on inside Mars’s debt stack, and the timing is anything but casual. On November 20, Mars fixed the pricing for cash tender offers spanning selected Mars and Kellanova senior notes, with holders facing a 5:00 p.m. New York deadline that same day. This is the kind of filing that looks like bond-market plumbing until you...

Continue Reading
TEN Holdings Raises $1.0 Million as Dilution Looms

Updated Category News Views 66

A Small Raise With a Loud Message Nothing says “we need room to breathe” quite like selling 1,492,500 new shares for $0.67 apiece. TEN Holdings closed a roughly $1.0 million gross equity offering on November 20, 2026, and investors in NASDAQ:XHLD ought to look at this for what it is: a modest cash infusion that comes with immediate dilution. The company gets capital;...

Continue Reading
Sidus Gains Argotec Order, but Investors Need the Math

Updated Category News Views 149

A Real Customer Signal, Minus the Revenue Figure An updated image is the least interesting detail in this release. Sidus Space has landed a purchase order from Argotec Group to manufacture cable assemblies for the HAWK satellite platform, with delivery expected in the first quarter of 2027. That is a legitimate operational win for NASDAQ:SIDU. It brings in a new...

Continue Reading
Saturn and Tileward Put GPU Memory Back to Work Now

Updated Category News Views 49

GPU memory is the tollbooth nobody notices until the whole AI highway backs up. Saturn Cloud’s new partnership with Tileward goes straight at that constraint: use compressed open-model weights, free memory on hardware already installed, and turn that reclaimed capacity into more tokens that an operator can actually sell. It is not glamorous. It may be one of the more...

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 78

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
Delayed Remodels Can Quietly Drain Your Home's Value

Updated Category News Views 73

A pinhole leak has a nasty talent for becoming a demolition budget. That is the plain lesson in Jason Marks' discussion of delayed remodeling for homeowners in Kernersville, North Carolina. People tend to see a worn bathroom, tired kitchen, or drafty window and think, “Not pretty, but it can wait.” Sometimes it can. Sometimes that little delay lets water, rot,...

Continue Reading
Tampa General's Food Bet Earns a 2026 Innovation Award

Updated Category News Views 41

Hospital meals have long been the punchline nobody bothered to fix, which is why Tampa General Hospital's latest recognition deserves a closer look. The not-for-profit academic health system was named the 2026 Inno Pick by the Tampa Bay Business Journal for its Food as Medicine initiative, its fifth straight year landing among the publication's Inno Award honorees. Awards...

Continue Reading

Top 5 Most Recently Viewed Articles

Ivalua Celebrates Winning Multiple Best Company Awards

Updated Category News Views 104

Ivalua Celebrates Its Recognition with Multiple Best Company Awards Ivalua, a leader in spend management solutions, is excited to share its recent achievements at the Comparably Awards. The company received accolades for Happiest Employees, Best Company Perks & Benefits, and Best Company Work-Life Balance. This recognition underscores Ivalua's commitment to creating an...

Continue Reading
Global Peace Index Reveals Increasing Conflict Trends

Updated Category News Views 371

The 2025 Global Peace Index: A Rising Tide of Conflict The recently released 2025 Global Peace Index (GPI) by the Institute for Economics & Peace (IEP) highlights a troubling trend of declining global peacefulness. The report indicates that we are witnessing a significant change in the global landscape, pointing to a stark reality where conditions leading to conflict are...

Continue Reading
Innovative Device Revolutionizes Painting Techniques and Efficiency

Updated Category News Views 227

Transformative Invention for Painters In the world of painting, efficiency and effectiveness are paramount. Inventors continually seek ways to improve the tools that workers use. One new device, the LOCK & ROLL, aims to enhance the painting experience significantly. Introduction to the LOCK & ROLL This innovative invention is designed to securely anchor paint rollers atop...

Continue Reading
Norfolk Southern's Leadership Crisis: Alan Shaw's Upcoming Exit

Updated Category News Views 130

Norfolk Southern at a Crossroads as Alan Shaw Faces Scrutiny Norfolk Southern Corporation is navigating a tense moment. Chief Executive Alan Shaw is under investigation for alleged ethical violations, including a purported relationship with a company employee. The review has raised questions about leadership, culture, and what accountability should look like at one of the...

Continue Reading
West USA Realty Partners with Zillow to Enhance Listings

Updated Category News Views 235

West USA Realty Embraces Transparency with Zillow West USA Realty, a leading name in the real estate industry, is taking a bold step by aligning with Zillow's standards for consumer access to property listings. This partnership reflects a mutual commitment to transparency and aims to enhance the experience for home buyers and sellers alike. Commitment to Consumers As the...

Continue Reading